Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

53
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
53
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

71
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
71
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

41
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
41
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

20
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
20
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

44
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
44

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RIBOFLAVIN deficiency in rheumatic Diseases: A call for clinical trials.

Rheumatology and immunology research·2026
Same author

The role of neuroimaging in the diagnosis of cerebral toxoplasmosis: a systematic review.

Radiologia brasileira·2026
Same author

Polyarteritis nodosa and antiphospholipid syndrome: a systematic review of a rare and challenging overlap between vasculitis and thrombotic vasculopathy.

Clinical rheumatology·2026
Same author

Defining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC).

Systematic reviews·2026
Same author

Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestations.

Expert review of precision medicine and drug development·2026
Same author

Antidotes in Homeopathy: Classical Doctrine, Clinical Relevance and Scientific Re-interpretation.

Homeopathy : the journal of the Faculty of Homeopathy·2026

Related Experiment Video

Updated: Sep 19, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

351

Safety of Accelerated Rituximab Infusion in Rheumatic Diseases: A Systematic Review.

Jozélio Freire de Carvalho1, Samuel de Oliveira Andrade2, Ana Tereza Amoedo Martinez3

  • 1Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEC), School of Nutrition, Federal University of Bahia, Basílio da Gama, 200, Canela, Salvador, BA, 40110-040, Brazil. jotafc@gmail.com.

Rheumatology and Therapy
|June 15, 2025
PubMed
Summary

Rapid rituximab (RTX) infusions are safe and efficient for autoimmune rheumatic diseases, comparable to standard rates. This approach reduces patient clinic time without increasing infusion reactions, supporting wider rheumatology adoption.

Keywords:
Biological therapyInfusion reactionRapid infusionRheumatic diseasesRituximab

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K

Related Experiment Videos

Last Updated: Sep 19, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

351
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Autoimmune rheumatic diseases (ARDs) often require treatment with rituximab (RTX).
  • Standard RTX infusion protocols can be time-consuming for patients.
  • Evaluating accelerated infusion protocols is crucial for improving patient convenience and healthcare efficiency.

Discussion:

  • This systematic review analyzed seven studies involving 538 patients with various ARDs.
  • Rapid RTX infusion protocols (90-120 minutes) were assessed for safety and feasibility.
  • Infusion reactions were monitored and graded using standardized criteria.

Key Insights:

  • Rapid RTX infusions demonstrated a low incidence of infusion reactions (3-15%), predominantly mild (Grades 1-2).
  • No severe (Grades 4-5) infusion reactions were reported with accelerated protocols.
  • Accelerated RTX infusion significantly reduced patient time spent in infusion clinics.

Outlook:

  • Rapid RTX infusion is a safe and efficient alternative for ARDs, comparable to standard protocols.
  • Findings support broader implementation of rapid infusion in rheumatology settings.
  • Further prospective studies are needed to validate these results and explore even shorter infusion durations.